Cargando…
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
BACKGROUND: The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group – Bone Tumor Study Group (GSF-GETO) national registry. METHODS: All patients with an osteosarcoma, registered between January...
Autores principales: | Penel-Page, Mathilde, Ray-Coquard, Isabelle, Larcade, Julie, Girodet, Magali, Bouclier, Laure, Rogasik, Muriel, Corradini, Nadège, Entz-Werle, Natacha, Brugieres, Laurence, Domont, Julien, Lervat, Cyril, Piperno-Neumann, Sophie, Pacquement, Helène, Bay, Jacques-Olivier, Gentet, Jean-Claude, Thyss, Antoine, Chaigneau, Loic, Narciso, Bérangère, Cornille, Helène, Blay, Jean-Yves, Marec-Bérard, Perrine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635968/ https://www.ncbi.nlm.nih.gov/pubmed/26541413 http://dx.doi.org/10.1186/s12885-015-1894-5 |
Ejemplares similares
-
High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group
por: Marec-Berard, Perrine, et al.
Publicado: (2014) -
The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014) -
Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
por: Thebault, Eric, et al.
Publicado: (2021) -
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study
por: Tabone, Marie-Dominique, et al.
Publicado: (2017) -
Observatoires du développement, observatoires pour le développement : actes du séminaire, Orstom, Paris, septembre 1994 /
Publicado: (1998)